13Z,16Z-Docosadienoic Acid
(Synonyms: 顺13,16-二十二碳二烯酸,cis-13,16-Docosadienoic Acid) 目录号 : GC16693A natural ω-6 PUFA
Cas No.:17735-98-7
Sample solution is provided at 25 µL, 10mM.
13Z,16Z-Docosadienoic acid is a natural ω-6 polyunsaturated fatty acid (PUFA) formed through a 2-carbon chain elongation of arachi donic acid. 13Z,16Z-Docosadienoic acid acts as an agonist of free fatty acid receptor 4 (FFAR4, also known as GPR120) [1].
Free fatty acids act as a source of energy and also function as signaling molecules which involved in regulating energy homeostasis. The endogenous ligands for FFAR4 are ω3-FAs, such as α-LA,DHA and EPA. FFAR4 has been involved in diverse physiological process such as anti-inflammation, insulin sensitization, release of gut peptides and alternation of food preference [2].
13Z,16Z-Docosadienoic acid strongly inhibited the secretion of ghrelin by isolated mouse gastric cells [1]. Dietary n-3 polyunsaturated fatty acids (PUFA) ameliorate several human diseases such as coronary heart disease, autoimmune and inflammatory disorders, diabetes, obesity and cancer [3]. This 20:2 PUFA has already been identified in fish, mammals, plants, and anaerobic fungi.
References:
[1]. X. Lu, X. Zhao, J. Feng, et al. Postprandial inhibition of gastric ghrelin secretion by long-chain fatty acid through GPR120 in isolated gastric ghrelin cells and mice. Am. J. Physiol. Gastrointest. Liver Physiol. 303(3), G367-376 (2012).
[2]. Kimura I. Omega-3 fatty acids and FFAR4[J]. Obesity and Diabetes: Energy Regulation by Free Fatty Acid Receptors, 2016: 29.
[3]. Ma D W L, Seo J, Switzer K C, et al. n-3 PUFA and membrane microdomains: a new frontier in bioactive lipid research[J]. The Journal of nutritional biochemistry, 2004, 15(11): 700-706.
Cas No. | 17735-98-7 | SDF | |
别名 | 顺13,16-二十二碳二烯酸,cis-13,16-Docosadienoic Acid | ||
化学名 | 13Z,16Z-docosadienoic acid | ||
Canonical SMILES | CCCCC/C=C\C/C=C\CCCCCCCCCCCC(O)=O | ||
分子式 | C22H40O2 | 分子量 | 336.6 |
溶解度 | ≤10mg/ml in ethanol;10mg/ml in DMSO;10mg/ml in dimethyl formamide | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 2.9709 mL | 14.8544 mL | 29.7089 mL |
5 mM | 0.5942 mL | 2.9709 mL | 5.9418 mL |
10 mM | 0.2971 mL | 1.4854 mL | 2.9709 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet